VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, vice president and CFO, will present at the Fifteenth NewsMakers in the Biotech Industry Conference at 3:30 p.m. (local time) on Thursday, September 4, 2008. The presentation will take place in room 311 of the Millennium Broadway Hotel & Conference Center in New York City.
The presentation will be webcast and can be accessed by going to the company’s website at http://ir.vivus.com.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. The pipeline includes: Qnexa™, which is in phase 3 for the treatment of obesity and phase 2 for the treatment of type 2 diabetes; Testosterone MDTS®, for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED). For more information on clinical trials and products, please visit the company's web site at http://www.vivus.com.
Contacts:
Timothy E. Morris, 650-934-5200
Chief
Financial Officer
or
Trout Group
Ian Clements (SF)
415-392-3385
Brian Korb (NYC) 646-378-2923